Are Investors Undervaluing Tenet Healthcare (THC) Right Now?
The article analyzes why Tenet Healthcare (THC) appears to be undervalued based on Zacks' value investing metrics. THC currently holds a Zacks Rank #2 (Buy) and an "A" grade for Value, supported by a PEG ratio of 0.81, significantly lower than its industry average of 1.87, and a P/CF ratio of 7.51, which is also favorable compared to its industry. These indicators, along with a strong earnings outlook, suggest THC is a promising value stock.
THC - Tenet Healthcare Corp Latest SEC Filings
This article provides a detailed financial overview of Tenet Healthcare Corp (THC), including key financial metrics, stock performance data, and insider/institutional ownership percentages. It highlights the company's market capitalization, revenue, earnings per share, and various valuation ratios, alongside recent stock performance across different timeframes. The content appears to be a snapshot of financial data and not a news article.
Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings
Tenet Healthcare Corporation (NYSE: THC) shares jumped over 6.5% following positive analyst coverage ahead of its Q2 2026 earnings report on July 24. While Bank of America and TD Cowen trimmed their price targets, both maintained "Buy" ratings, citing sector-wide pressures but confidence in Tenet's strong, ASC-heavy portfolio. The article highlights Tenet's robust fundamentals, including 14% revenue growth over three years, high margins, and a low P/E ratio, despite elevated leverage.
Tenet Healthcare Jumps 5.7% Amid Sector-Wide Rally
Tenet Healthcare Corporation saw its stock surge 5.7% to $202.03, participating in a broader sector-wide rally that also benefited peers like HCA and UHS. This movement appears to be driven by shifting investor sentiment towards hospital operators, possibly due to improving fundamentals, rather than any company-specific news. The strong performance, with significant trading volume, suggests renewed investor confidence in the healthcare facilities market.
Cantor Fitzgerald reiterates Tenet Healthcare stock rating on staffing trends
Cantor Fitzgerald maintained its Overweight rating and $245.00 price target for Tenet Healthcare (NYSE: THC), noting stable hiring in acute and ASC/Outpatient nursing but weaker physician data, with increased openings concentrated in Florida and Arizona. InvestingPro's Fair Value analysis suggests the stock is currently undervalued. The report also highlighted Tenet Healthcare's strong Q1 2026 EPS, an upgrade by Moody's Ratings due to sustained deleveraging, and positive foot traffic trends indicating growth in hospital volumes.
Tenet Healthcare Stock Climbs As Analysts Trim Targets
Tenet Healthcare (THC) stock has risen by 8.83% despite analysts trimming their price targets, indicating that the market is focusing on the company's strong financial performance rather than sector-wide headwinds. The company reported robust quarterly revenue, high profitability margins, and significant free cash flow, suggesting efficiency in turning revenue into earnings. Traders are watching for the upcoming Q2 2026 earnings release on July 24, 2026, as a key catalyst.
Tenet Healthcare Stock Climbs As Analysts Trim Targets
Tenet Healthcare (THC) stock has risen by 8.56% due to strong earnings momentum and improved hospital utilization, even as analysts trim price targets while maintaining bullish ratings. Bank of America and TD Cowen both lowered their targets for THC, citing sector-wide pressures and weaker hospital/surgical volumes, not company-specific issues, signaling a recalibration of expectations rather than a loss of confidence. The company's Q2 2026 earnings, set for July 24, 2026, are a near-term catalyst, with traders watching how its solid margins and cash flow support the current uptrend despite the analyst adjustments.
Tenet Healthcare Jumps 5.7% Amid Sector-Wide Rally
Tenet Healthcare Corporation saw a 5.7% increase, closing at $202.03, as part of a broader rally in the healthcare sector, with other hospital operators like HCA and UHS also experiencing significant gains. This sector-wide movement suggests renewed investor confidence in hospital operators due to possible shifts in reimbursement trends, utilization patterns, or healthcare policy expectations, rather than any company-specific news for Tenet. Investors should monitor if the sector momentum continues and consider upcoming earnings reports for confirmation of improved fundamentals.
Why Tenet Healthcare (THC) Stock Is Up Today
Tenet Healthcare (THC) shares rose 7.6% after Cantor Fitzgerald reiterated an Overweight rating and a $245.00 price target, citing improving patient acuity. This positive outlook is supported by strong first-quarter 2026 earnings and a recent credit rating upgrade from Moody's due to debt reduction and earnings growth. Despite the year-to-date increase of 2.7%, the stock is still trading below its 52-week high.
CMS rule aims to lower Medicare costs at hospitals, ambulatory service centers
The Centers for Medicare & Medicaid Services (CMS) has proposed a new rule to modify how hospital outpatient departments and ambulatory surgical centers are reimbursed for services and drugs provided to Medicare beneficiaries. Starting in 2027, these changes aim to lower Medicare costs. A key part of this proposal involves adjustments to payments for certain medications.
Cantor Fitzgerald reiterates Tenet Healthcare stock rating at Overweight
Cantor Fitzgerald has reiterated its Overweight rating on Tenet Healthcare (NYSE:THC) with a price target of $245.00, noting the stock is currently trading at $187.08. The firm's analysis points to the company being undervalued and highlights improving acuity in Tenet Healthcare's operations despite a decline in outpatient pricing estimates. Recent developments, including strong first-quarter 2026 earnings, a Moody's Ratings upgrade, and positive foot traffic trends, underscore the company's financial and operational progress.
Beyond the Hospital Walls: Why USPI Is Becoming Tenet's Growth Engine
Tenet Healthcare Corporation is seeing its growth increasingly driven by its United Surgical Partners International (USPI) segment, which focuses on ambulatory surgery centers. USPI generated strong first-quarter 2026 results with a 6.1% year-over-year increase in adjusted EBITDA and significant investment in new ASCs. This strategy positions Tenet to capitalize on the ongoing shift towards lower-cost outpatient care, enhancing long-term growth and profitability, similar to peers like Surgery Partners and HCA Healthcare.
Tenet Healthcare Corporation (THC) Stock Analysis: Unlocking a 28.67% Potential Upside in the Healthcare Sector
Tenet Healthcare Corporation (NYSE: THC) is presented as a compelling investment opportunity in the healthcare sector, with analysts projecting a potential upside of 28.67%. The company demonstrates strong financial performance, including a 30.29% return on equity and over $3 billion in free cash flow, alongside a positive analyst outlook and a solid position in its market. Despite not offering dividends, its focus on reinvestment and current stock metrics suggest it could be an attractive addition for investors seeking growth in healthcare.
Zacks Industry Outlook Highlights Tenet Healthcare, Universal Health Services, Acadia Healthcare and Community Health Systems
The Zacks Medical-Hospital industry is undergoing a transformation with a shift towards lower-cost care settings, leading to challenges like labor costs and reimbursement uncertainty for traditional hospitals. Despite these pressures, the industry has a positive outlook according to Zacks Industry Rank. The article highlights four hospital stocks—Tenet Healthcare, Universal Health Services, Acadia Healthcare, and Community Health Systems—that are adapting through operational streamlining, cost discipline, and investments in higher-growth service lines.
Price to sales forward of Tenet Healthcare Corporation – NYSE:THC
This page displays the "Price to sales forward" metric for Tenet Healthcare Corporation (NYSE: THC). The content focuses on financial data for the company, accessible through TradingView, and includes options to view various financial aspects like overview, news, documents, and forecasts. The page itself does not provide specific values for the metric but allows users to access it.
Tenet Healthcare soars 70% after InvestingPro Fair Value alert By Investing.com
Tenet Healthcare (NYSE: THC) shares have risen 70% since April 2025 after InvestingPro's Fair Value models identified the stock as significantly undervalued. The company's solid fundamentals, including its growing ambulatory segment, effective cost management, and improving balance sheet, supported this growth. InvestingPro's comprehensive valuation methodology proved accurate, with THC exceeding its projected target and demonstrating the power of disciplined analysis in uncovering market inefficiencies.
Is Tenet Healthcare (THC) Undervalued Following Analyst Upgrades Ahead Of July Earnings?
Tenet Healthcare (THC) has garnered investor attention due to recent stock gains and upcoming earnings on July 24, 2026, supported by positive analyst revisions. Despite a modest year-to-date share price decline, the stock has shown an 8.85% one-year total shareholder return and a recent 9.52% seven-day gain, suggesting building momentum. Analysts currently view THC as undervalued at $189.00, compared to an average target of $243.19 and an intrinsic value gap of about 60%, largely due to its repositioning towards a diversified care network.
THC Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Tenet Healthcare Corporation (THC) stock, based on analyst opinions. It includes current stock performance metrics, historical highs and lows, market capitalization, and details on recent earnings and revenue. The article also addresses frequently asked questions about investing in THC and mentions its next earnings report date.
Tenet Healthcare Corporation Actuals & Estimates (NYSE:THC)
This article provides an overview of Tenet Healthcare Corporation (NYSE: THC), including its current stock performance, analyst forecasts, financial data, and future earnings estimates. It highlights recent stock price movements, market capitalization, and upcoming earnings release dates, along with historical price data and financial performance metrics.
The ambulatory surgical centers from Tenet Healthcare Corp - a quiet backbone of US elective care
This article highlights how Tenet Healthcare Corp's ambulatory surgical centers form a critical, yet often unacknowledged, part of the US healthcare system. These centers provide cost-effective, same-day surgical care for elective procedures, distinguishing them from traditional hospitals. The text discusses their operational model, benefits for patients and surgeons, and their strategic importance to Tenet's financials, while also touching upon regulatory aspects and investor appeal.
Precision Trading with Tenet Healthcare Corporation (THC) Risk Zones
This article provides a detailed trading analysis for Tenet Healthcare Corporation (THC), highlighting a neutral near-term outlook despite strong mid-term sentiment, which might be stalling. It presents three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry zones, targets, and stop losses. The analysis emphasizes a significant 53.9:1 risk-reward setup targeting a 15.7% gain against 0.3% risk.
Tenet Healthcare (THC) Ascends While Market Falls: Some Facts to Note
Tenet Healthcare (THC) closed up 1.19% while the broader market declined, outperforming the S&P 500, Dow, and Nasdaq. The stock has seen a 2.86% increase over the past month, leading its sector. Upcoming earnings are projected to show a 1.49% EPS increase and 2.27% revenue growth year-over-year.
Tenet Healthcare (THC) Ascends While Market Falls: Some Facts to Note
Tenet Healthcare (THC) showed a gain of 1.19% in a recent trading session, outperforming the broader market which saw declines in the S&P 500, Dow, and Nasdaq. The stock has also risen by 2.86% in the past month, signaling positive momentum within the Medical sector. Analysts anticipate strong earnings and revenue growth for the company's upcoming report, with revisions indicating a favorable outlook based on the Zacks Rank #2 (Buy) rating.
Tenet Healthcare (THC) Ascends While Market Falls: Some Facts to Note
Tenet Healthcare (THC) recently closed up 1.19% while the broader market fell, showing strength with a 2.86% gain over the past month. The company is set to release its earnings on July 24, 2026, with projected increases in EPS and revenue. With a Zacks Rank of #2 (Buy) and favorable analyst estimate revisions, THC appears to be in a strong position within the Medical - Hospital industry.
Tenet to release Q2 2026 results July 24, call at 10:30 a.m. CT
Tenet Healthcare Corporation (NYSE: THC) announced it will release its second quarter 2026 results before market open on Friday, July 24, 2026. A conference call is scheduled for 10:30 a.m. CT (11:30 a.m. Eastern Time) that same day, with a webcast accessible via their investor relations website. Tenet Healthcare is a diversified healthcare services company based in Dallas, operating ambulatory surgery centers, hospitals, and providing revenue cycle management services through its Conifer Health Solutions subsidiary.
Tenet Healthcare to report Q2FY26 results on July 24
Tenet Healthcare Corporation announced it will release its second quarter 2026 results before market open on Friday, July 24, 2026. A conference call is scheduled for 10:30 a.m. CT (11:30 a.m. Eastern Time) on the same day to discuss the company's financial performance. Investors can access a live webcast and audio archive via the company's investor relations website.
THC Maintained by TD Cowen -- Price Target Lowered to $233
TD Cowen has maintained a 'Buy' rating for Tenet Healthcare (THC) but slightly lowered its price target from $242 to $233. GuruFocus indicates that THC is currently 8.0% overvalued with a GF Value™ of $164.51, despite having a strong GF Score™ of 80, which suggests good long-term potential. Insider activity shows $1.5 million in shares sold over the last three months, which investors should consider when evaluating the stock.
Press Release: Tenet to Report Its Second Quarter 2026 Results on July 24
Tenet Healthcare Corporation announced it will release its second-quarter 2026 financial results on July 24, 2026. The company will also host a conference call and live webcast to discuss these results on the same day. Investors can access the webcast and related materials via the Tenet website.
Tenet to Report Its Second Quarter 2026 Results on July 24
Tenet Healthcare Corporation (NYSE: THC) announced it will release its second quarter 2026 results before the market opens on Friday, July 24, 2026. This will be followed by a conference call at 10:30 a.m. CT (11:30 a.m. Eastern Time). A live webcast and archive will be available on the investor relations section of Tenet’s website.
Tenet to Report Its Second Quarter 2026 Results on July 24
Tenet Healthcare Corporation will announce its second quarter 2026 financial results before the market opens on Friday, July 24, 2026. A conference call will follow at 10:30 a.m. CT (11:30 a.m. Eastern Time), with a live webcast and audio archive accessible via the investor relations section of Tenet’s website. The company is a diversified healthcare services provider headquartered in Dallas.
THC - Tenet Healthcare Corp Stock Price and Quote
This page provides a detailed overview of Tenet Healthcare Corp (THC) stock, including its latest price, financial performance metrics, and analyst ratings. It also lists recent news articles related to the company and insider trading activities.
Judge denies Leapfrog Group’s appeal of Tenet lawsuit ruling
A federal judge has denied The Leapfrog Group's motion to reverse an earlier ruling against its hospital safety grading methodology. This decision comes as part of the ongoing lawsuit involving Tenet. The article, authored by Hayley DeSilva, was published on June 18, 2026.
Tenet Healthcare Corporation (THC) is Attracting Investor Attention: Here is What You Should Know
Tenet Healthcare Corporation (THC) is drawing investor attention due to its recent stock performance and strong underlying fundamentals. The article highlights the importance of earnings estimate revisions in determining a stock's future direction, noting Tenet's Zacks Rank #2 (Buy). It also reviews the company's projected revenue growth, recent earnings surprises, and favorable valuation, suggesting potential for outperformance.
Judge denies Leapfrog’s motion to reconsider Tenet lawsuit ruling
A federal judge has denied The Leapfrog Group's motion to reconsider a previous ruling in its lawsuit with Tenet, which targeted Leapfrog's hospital safety grading methodology. The article indicates this is an update to an ongoing legal dispute regarding hospital safety ratings.
Tenet Healthcare Corp (THC) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Tenet Healthcare Corp (THC), highlighting its current earnings forecast score of 8.17 and ranking within the Healthcare Providers & Services industry. It details analysts' price targets, showing an average of $240.00 with a high of $260.00 and a low of $159.00, and notes that most analysts recommend a "Buy" for the stock. Key financial data such as expected revenue for the next quarter and past/future EPS figures are also included.
Tenet Healthcare Corp (THC) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes Tenet Healthcare Corp (THC)'s financial health, noting its stable financial status and high operating efficiency. The company's financial score is 8.69, ranking 14th out of 76 in its industry. Recent quarterly results show a 2.78% year-over-year revenue increase and a significant 72.91% increase in net profit.
Tenet Healthcare (THC) Bank of America Global Healthcare Conference 2026 Summary
Tenet Healthcare (THC) presented at the Bank of America Global Healthcare Conference 2026, highlighting strong Q1 performance with improved respiratory volumes and outperforming acute business, particularly in Florida. The company expressed confidence in meeting its full-year guidance, driven by robust hospital segment margins, effective expense management, and a commitment to achieving 10% core growth between 2025 and 2026 through high-acuity expansion and technological initiatives. Recent financial reports and events also underscore significant growth in net income, EBITDA, and strategic transactions.
BofA Maintains Buy Rating on Tenet Healthcare (THC)
BofA has maintained its Buy rating on Tenet Healthcare (THC) but lowered its price target to $210 from $230, citing lower multiples due to a weak utilization backdrop. Other analysts from Barclays and Morgan Stanley also adjusted their price targets while maintaining Overweight ratings, acknowledging Tenet's strong Q1 execution despite industry headwinds. The company reported Q1 adjusted EPS of $4.82 and revenue of $5.37 billion, demonstrating disciplined operations and growth in both Ambulatory and Hospital segments.
Is Now The Time To Look At Buying Tenet Healthcare Corporation (NYSE:THC)?
This article evaluates Tenet Healthcare Corporation (NYSE:THC) as a potential investment opportunity. It likely delves into financial metrics, market performance, and other factors to assess whether it's a good time for investors to consider buying shares in the company.
THC Technical Analysis & Stock Price Forecast
Tenet Healthcare Corp (THC) currently shows a "Strong Sell" technical sentiment based on an aggregation of 10 technical signals with 8 indicating sell and 2 indicating buy. Key indicators like the MACD and various moving averages suggest bearish momentum, with THC trading below its 60-day and 200-day moving averages. The article also provides specific support and resistance levels for traders to monitor.
Did Moody’s Credit Upgrade Just Reframe Tenet Healthcare’s (THC) Deleveraging Story for Investors?
Moody’s recently upgraded Tenet Healthcare Corporation's credit rating to Ba2 with a stable outlook, acknowledging the company's sustained deleveraging efforts, strong EBITDA, and debt reduction. While this validates Tenet's disciplined financial policies and focus on ambulatory care, the article notes that investors still need to consider operational execution, projected earnings softening, and governance concerns like high CEO pay and insider selling. Despite the upgrade, some analyses suggest Tenet's shares might still be overvalued.
Does Tenet Healthcare’s (THC) Credit Upgrade Quietly Redefine Its Ambulatory‑First Investment Story?
Tenet Healthcare Corporation (THC) recently received a credit upgrade from Moody’s, moving its Corporate Family Rating to Ba2 from Ba3, citing sustained deleveraging and strong EBITDA. This upgrade reinforces the company's investment narrative focused on high-margin ambulatory care, strategic buybacks, and debt management. While the upgrade and strong Q1 2026 results are positive catalysts, investors should also consider risks like softer future earnings forecasts, high leverage, and insider selling.
Tenet Healthcare Corporation (THC) is a trending stock: Facts to know before betting on it
This article identifies Tenet Healthcare Corporation (THC) as a currently trending stock. It advises potential investors to understand key facts about the company before making an investment decision. The content will likely delve into various aspects of THC's financial health, market position, or recent performance.
Tenet Healthcare Corporation Balance Sheet – XETR:THC1
Tenet Healthcare Corporation's financial position for Q1 26 shows total assets of 27.01 B EUR, a 6.88% increase from Q4 25. Total liabilities also rose by 9.75% to 19.35 B EUR in the same quarter. The report provides an overview of the company's balance sheet, income statement, and cash flow data, with historical figures available up to Q4 25.
ETFs Investing in Tenet Healthcare Corporation Stocks
This article lists various ETFs that hold Tenet Healthcare Corporation (THC1) stocks, providing details such as market value, weight, issuer, management style, focus, expense ratio, AUM, price, change, related volume, and 3-year NAV total return. The ETFs cover a range of investment strategies including passive, active, and holdings across total market, mid-cap, small-cap, large-cap, and healthcare sectors. This information is intended to help investors identify funds that offer diversified exposure to Tenet Healthcare while potentially lowering risk.
Moody’s upgrades Tenet Healthcare rating on deleveraging
Moody's Ratings has upgraded Tenet Healthcare Corporation's Corporate Family Rating to Ba2 from Ba3, with a stable outlook, citing sustained deleveraging and strong EBITDA growth. The upgrade also reflects Tenet's disciplined financial policies and expectations for continued expansion in its ambulatory care business. The company's significant scale, good business diversity, and strong liquidity contributed to the improved rating.
Tenet Healthcare Corporation (THC) Is a Trending Stock: Facts to Know Before Betting on It
Tenet Healthcare Corporation (THC) is a trending stock due to recent investor interest, but its performance has lagged the S&P 500 and its industry. The article analyzes THC's earnings estimate revisions, revenue growth, past results, and valuation to provide insights for potential investors. Currently, Tenet holds a Zacks Rank #3 (Hold), suggesting it may perform in line with the broader market in the near term.
Is Tenet Healthcare Stock Optimizing Returns Through the Denominator Effect?
Tenet Healthcare (THC) is increasing shareholder returns by consistently reducing its share count, a strategy known as the "denominator effect." This has led to EPS growth outpacing net income growth, resulting in significant stock price appreciation. The company effectively generates cash flow to fund operations and share buybacks, maintaining financial health despite reliance on this method.
Is Tenet Healthcare Corp (THC) a Bargain After 3.8% Drop? GF Value Says Undervalued
Tenet Healthcare Corp (THC) shares recently dropped 3.8%, making its current price of $163.60 slightly undervalued compared to its GF Value™ of $164.27. Despite a strong GF Score™ of 80/100, the stock has seen significant insider selling totaling $12.5 million, raising concerns about its short-term prospects and financial strength. Investors are advised to proceed with caution due to the downward trend and insider sentiment, even though historical P/E suggests it's trading at a discount.
Insider Selling Alert: J Kerrey Sells Shares of Tenet Healthcare Corp (THC)
J Kerrey, a director at Tenet Healthcare Corp (THC), sold 5,638 shares of the company on May 28, 2026, reducing his holdings to 16,804 shares. The company's stock was trading at $174.52, indicating it is "Fairly Valued" based on its GuruFocus Value. This transaction is part of a trend of 17 insider sells and no buys over the past year for Tenet Healthcare.
